{
    "clinical_study": {
        "@rank": "152896", 
        "arm_group": [
            {
                "arm_group_label": "Rep", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Met", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Rep + met", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Asia. The aim of this trial is to compare repaglinide and\n      metformin administered alone or in combination in subjects with type 2 diabetes."
        }, 
        "brief_title": "Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes", 
        "completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previously treated with oral hypoglycaemic agents (OHA) as monotherapy (if metformin,\n             less than 1500 mg daily)\n\n          -  Body Mass Index (BMI) of  21-35 kg/m^2\n\n          -  HbA1c (glycosylated haemoglobin A1c) between 7.0-10%\n\n        Exclusion Criteria:\n\n          -  Treatment with insulin within the last 3 months preceding the trial\n\n          -  Uncontrolled treated or untreated hypertension (systolic blood pressure above or\n             equal to 180 mm Hg, and/or diastolic blood pressure above 105 mm Hg)\n\n          -  Participation in any other clinical trial within 30 days of screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720290", 
            "org_study_id": "AGEE-3018"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Rep", 
                    "Rep + met"
                ], 
                "description": "Dose individually adjusted", 
                "intervention_name": "repaglinide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Met", 
                "description": "Dose individually adjusted", 
                "intervention_name": "metformin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Rep + met", 
                "description": "Dose at 1000 mg/day", 
                "intervention_name": "metformin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Repaglinide", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 31, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100029"
                }
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A 3-month, Open-label, Randomized, Multi-center Study of Repaglinide in Combination With Metformin as Compared to Metformin or Repaglinide Given as Monotherapy for the Treatment of Type 2 Diabetes.", 
        "overall_official": {
            "affiliation": "Novo Nordisk (China) Pharmaceuticals Co., Ltd", 
            "last_name": "Cheng Yuwei", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in HbA1c (glycosylated haemoglobin A1c)", 
            "safety_issue": "No"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720290"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": [
            {
                "measure": "Fasting blood glucose (FBG)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "1-hour post prandial blood glucose (PPBG)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Incidence of hypoglycemic episodes", 
                "safety_issue": "No"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}